Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Peter Sinn

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
Angewandte Chemie (International Ed. in English)|September 13, 2011
Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissuesNikola Gaidzik, Anton Kaiser, Danuta Kowalczyk, et al.
Cancer Epidemiology|June 22, 2014
Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intakePetra Seibold, Alina Vrieling, Judith Heinz, et al.
Virchows Archiv : an International Journal of Pathology|January 26, 2005
Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breastSebastian Aulmann, Philipp A Schnabel, Birgit Helmchen, et al.
International Journal of Cancer|July 13, 2002
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 6, 2013
Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor lossLisa Braun, Friederike Mietzsch, Petra Seibold, et al.
Anti-Cancer Drugs|September 16, 2005
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trialAndreas Schneeweiss, Florian Schuetz, Christian Rudlowski, et al.
Anticancer Research|November 5, 2014
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancerAndreas Schneeweiss, Julia Seitz, Katharina Smetanay, et al.
International Journal of Molecular Sciences|September 9, 2020
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 SamplesKatharina Kriegsmann, Christa Flechtenmacher, Jörg Heil, et al.
Stem Cells (Dayton, Ohio)|January 18, 2002
Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Anti-Cancer Drugs|April 13, 2004
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapyAndreas Schneeweiss, Julia Katretchko, Hans-Peter Sinn, et al.
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
Angewandte Chemie (International Ed. in English)|September 13, 2011
Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissuesNikola Gaidzik, Anton Kaiser, Danuta Kowalczyk, et al.
Cancer Epidemiology|June 22, 2014
Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort - Differential effects by tumour subtype, NAT2 status, BMI and alcohol intakePetra Seibold, Alina Vrieling, Judith Heinz, et al.
Virchows Archiv : an International Journal of Pathology|January 26, 2005
Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breastSebastian Aulmann, Philipp A Schnabel, Birgit Helmchen, et al.
International Journal of Cancer|July 13, 2002
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 6, 2013
Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor lossLisa Braun, Friederike Mietzsch, Petra Seibold, et al.
Anti-Cancer Drugs|September 16, 2005
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trialAndreas Schneeweiss, Florian Schuetz, Christian Rudlowski, et al.
Anticancer Research|November 5, 2014
Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancerAndreas Schneeweiss, Julia Seitz, Katharina Smetanay, et al.
International Journal of Molecular Sciences|September 9, 2020
Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 SamplesKatharina Kriegsmann, Christa Flechtenmacher, Jörg Heil, et al.
Stem Cells (Dayton, Ohio)|January 18, 2002
Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
Anti-Cancer Drugs|April 13, 2004
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapyAndreas Schneeweiss, Julia Katretchko, Hans-Peter Sinn, et al.
Pageof 12